422 related articles for article (PubMed ID: 24349052)
21. Emerging genetic therapies to treat Duchenne muscular dystrophy.
Nelson SF; Crosbie RH; Miceli MC; Spencer MJ
Curr Opin Neurol; 2009 Oct; 22(5):532-8. PubMed ID: 19745732
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of nonsense-mediated mRNA decay may improve stop codon read-through therapy for Duchenne muscular dystrophy.
Amar-Schwartz A; Cohen Y; Elhaj A; Ben-Hur V; Siegfried Z; Karni R; Dor T
Hum Mol Genet; 2023 Jul; 32(15):2455-2463. PubMed ID: 37145099
[TBL] [Abstract][Full Text] [Related]
23. The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy.
Brogna C; Coratti G; Rossi R; Neri M; Messina S; Amico A; Bruno C; Lucibello S; Vita G; Berardinelli A; Magri F; Ricci F; Pedemonte M; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Politano L; Comi GP; Sansone VA; Albamonte E; Donati A; Bertini E; Goemans N; Previtali S; Bovis F; Pane M; Ferlini A; Mercuri E;
Neuromuscul Disord; 2021 Jun; 31(6):479-488. PubMed ID: 33773883
[TBL] [Abstract][Full Text] [Related]
24. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
Kerem E; Konstan MW; De Boeck K; Accurso FJ; Sermet-Gaudelus I; Wilschanski M; Elborn JS; Melotti P; Bronsveld I; Fajac I; Malfroot A; Rosenbluth DB; Walker PA; McColley SA; Knoop C; Quattrucci S; Rietschel E; Zeitlin PL; Barth J; Elfring GL; Welch EM; Branstrom A; Spiegel RJ; Peltz SW; Ajayi T; Rowe SM;
Lancet Respir Med; 2014 Jul; 2(7):539-47. PubMed ID: 24836205
[TBL] [Abstract][Full Text] [Related]
25. Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy.
Kayali R; Ku JM; Khitrov G; Jung ME; Prikhodko O; Bertoni C
Hum Mol Genet; 2012 Sep; 21(18):4007-20. PubMed ID: 22692682
[TBL] [Abstract][Full Text] [Related]
26. [Nonsense readthrough therapy for Duchenne muscular dystrophy].
Takeshima Y
Rinsho Shinkeigaku; 2014; 54(12):1074-6. PubMed ID: 25672712
[TBL] [Abstract][Full Text] [Related]
27. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
[TBL] [Abstract][Full Text] [Related]
28. Read-through approach for stop mutations in Duchenne muscular dystrophy. An update.
Politano L
Acta Myol; 2021 Mar; 40(1):43-50. PubMed ID: 33870095
[TBL] [Abstract][Full Text] [Related]
29. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.
Malik V; Rodino-Klapac LR; Viollet L; Wall C; King W; Al-Dahhak R; Lewis S; Shilling CJ; Kota J; Serrano-Munuera C; Hayes J; Mahan JD; Campbell KJ; Banwell B; Dasouki M; Watts V; Sivakumar K; Bien-Willner R; Flanigan KM; Sahenk Z; Barohn RJ; Walker CM; Mendell JR
Ann Neurol; 2010 Jun; 67(6):771-80. PubMed ID: 20517938
[TBL] [Abstract][Full Text] [Related]
30. Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay.
Lentini L; Melfi R; Di Leonardo A; Spinello A; Barone G; Pace A; Palumbo Piccionello A; Pibiri I
Mol Pharm; 2014 Mar; 11(3):653-64. PubMed ID: 24483936
[TBL] [Abstract][Full Text] [Related]
31. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis.
Wilschanski M; Miller LL; Shoseyov D; Blau H; Rivlin J; Aviram M; Cohen M; Armoni S; Yaakov Y; Pugatsch T; Cohen-Cymberknoh M; Miller NL; Reha A; Northcutt VJ; Hirawat S; Donnelly K; Elfring GL; Ajayi T; Kerem E
Eur Respir J; 2011 Jul; 38(1):59-69. PubMed ID: 21233271
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy for muscular dystrophy: lessons learned and path forward.
Mendell JR; Rodino-Klapac L; Sahenk Z; Malik V; Kaspar BK; Walker CM; Clark KR
Neurosci Lett; 2012 Oct; 527(2):90-9. PubMed ID: 22609847
[TBL] [Abstract][Full Text] [Related]
33. [Mutation-specific treatments for Duchenne muscular dystrophy].
Matsuo M; Takeshima Y
Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
[TBL] [Abstract][Full Text] [Related]
34. A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy.
Landfeldt E; Sejersen T; Tulinius M
Acta Paediatr; 2019 Feb; 108(2):224-230. PubMed ID: 30188594
[TBL] [Abstract][Full Text] [Related]
35. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
[TBL] [Abstract][Full Text] [Related]
36. Readthrough strategies for stop codons in Duchenne muscular dystrophy.
Aurino S; Nigro V
Acta Myol; 2006 Jun; 25(1):5-12. PubMed ID: 17039975
[TBL] [Abstract][Full Text] [Related]
37. Treatment with ataluren in four symptomatic Duchenne carriers. A pilot study.
Dori A; Scutifero M; Passamano L; Zoppi D; Ruggiero L; Trabacca A; Politano L
Acta Myol; 2024; 43(1):8-15. PubMed ID: 38586166
[TBL] [Abstract][Full Text] [Related]
38. A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy.
Kimura S; Ito K; Miyagi T; Hiranuma T; Yoshioka K; Ozasa S; Matsukura M; Ikezawa M; Matsuo M; Takeshima Y; Miike T
Brain Dev; 2005 Sep; 27(6):400-5. PubMed ID: 16122626
[TBL] [Abstract][Full Text] [Related]
39. Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review.
Pascual-Morena C; Cavero-Redondo I; Álvarez-Bueno C; Mesas AE; Pozuelo-Carrascosa D; Martínez-Vizcaíno V
Ann Clin Transl Neurol; 2020 Sep; 7(9):1738-1752. PubMed ID: 33325654
[TBL] [Abstract][Full Text] [Related]
40. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon.
Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M
Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
